ezh2 overexpression plasmid Search Results


ezh2 sirna  (Shanghai Genechem Ltd)
90
Shanghai Genechem Ltd ezh2 sirna
Ezh2 Sirna, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ezh2 sirna/product/Shanghai Genechem Ltd
Average 90 stars, based on 1 article reviews
ezh2 sirna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ezh2 overexpression plasmid  (Vigene Biosciences)
90
Vigene Biosciences ezh2 overexpression plasmid
<t>EZH2</t> regulates H3K27me3 enrichment on the miR-30d promotor. ( a ) Genomic views of the H3K27me3 modification of miR-30d related to transverse aortic constriction (TAC) induced cardiac hypertrophy (GSE93752). ( b ) qRT-PCR analysis of the expression of H3K27 methyltransferase (EZH1 and EZH2) and demethylase (KDM6A and KDM6B) mRNA in neonatal rat cardiomyocytes (NRCMs) treated with phenylephrine (PE, n =6 per group) and angiotensin II (Ang II, n = 6 per group). ( c ) Western blot analysis of the expression of EZH2 protein level in NRCMs treated with PE ( n = 6 per group) and Ang II ( n = 6 per group). ( d ) Dual-luciferase reporter assay showed the regulation between EZH2 and miR-30d in AC16 ( n = 6 per group). ( e ) ChIP assay was performed to detect EZH2 binding and H3K27me3 enrichment on the miR-30d promotor region in AC16 ( n = 3 per group). ( f ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 <t>overexpression</t> plasmid (OE) or negative control Fugw plasmid for 48 h ( n = 3 per group). ( g ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 siRNA or control siRNA ( n = 3 per group). ( h ) Left, Representative immunofluorescence image of a-actinin (red)- and DAPI (blue)-stained NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE for 48 h. Scale bar, 100 μm. Right, Quantification of the average cell surface areas of NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE. ( n = 4 per group, number of CM≥ 50 cells per sample). Data are presented as mean±SD. Statistical significance was determined by Student t test (b-c, e) and two-way ANOVA test with post hoc tukey (d, f-h). *, P < 0.05; **, P < 0.01 and ***, P < 0.001.
Ezh2 Overexpression Plasmid, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ezh2 overexpression plasmid/product/Vigene Biosciences
Average 90 stars, based on 1 article reviews
ezh2 overexpression plasmid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


EZH2 regulates H3K27me3 enrichment on the miR-30d promotor. ( a ) Genomic views of the H3K27me3 modification of miR-30d related to transverse aortic constriction (TAC) induced cardiac hypertrophy (GSE93752). ( b ) qRT-PCR analysis of the expression of H3K27 methyltransferase (EZH1 and EZH2) and demethylase (KDM6A and KDM6B) mRNA in neonatal rat cardiomyocytes (NRCMs) treated with phenylephrine (PE, n =6 per group) and angiotensin II (Ang II, n = 6 per group). ( c ) Western blot analysis of the expression of EZH2 protein level in NRCMs treated with PE ( n = 6 per group) and Ang II ( n = 6 per group). ( d ) Dual-luciferase reporter assay showed the regulation between EZH2 and miR-30d in AC16 ( n = 6 per group). ( e ) ChIP assay was performed to detect EZH2 binding and H3K27me3 enrichment on the miR-30d promotor region in AC16 ( n = 3 per group). ( f ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 overexpression plasmid (OE) or negative control Fugw plasmid for 48 h ( n = 3 per group). ( g ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 siRNA or control siRNA ( n = 3 per group). ( h ) Left, Representative immunofluorescence image of a-actinin (red)- and DAPI (blue)-stained NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE for 48 h. Scale bar, 100 μm. Right, Quantification of the average cell surface areas of NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE. ( n = 4 per group, number of CM≥ 50 cells per sample). Data are presented as mean±SD. Statistical significance was determined by Student t test (b-c, e) and two-way ANOVA test with post hoc tukey (d, f-h). *, P < 0.05; **, P < 0.01 and ***, P < 0.001.

Journal: eBioMedicine

Article Title: Targeting miR-30d reverses pathological cardiac hypertrophy

doi: 10.1016/j.ebiom.2022.104108

Figure Lengend Snippet: EZH2 regulates H3K27me3 enrichment on the miR-30d promotor. ( a ) Genomic views of the H3K27me3 modification of miR-30d related to transverse aortic constriction (TAC) induced cardiac hypertrophy (GSE93752). ( b ) qRT-PCR analysis of the expression of H3K27 methyltransferase (EZH1 and EZH2) and demethylase (KDM6A and KDM6B) mRNA in neonatal rat cardiomyocytes (NRCMs) treated with phenylephrine (PE, n =6 per group) and angiotensin II (Ang II, n = 6 per group). ( c ) Western blot analysis of the expression of EZH2 protein level in NRCMs treated with PE ( n = 6 per group) and Ang II ( n = 6 per group). ( d ) Dual-luciferase reporter assay showed the regulation between EZH2 and miR-30d in AC16 ( n = 6 per group). ( e ) ChIP assay was performed to detect EZH2 binding and H3K27me3 enrichment on the miR-30d promotor region in AC16 ( n = 3 per group). ( f ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 overexpression plasmid (OE) or negative control Fugw plasmid for 48 h ( n = 3 per group). ( g ) ChIP assay was performed to detect H3K27me3 level enrichment on the miR-30d promotor region when AC16 was treated with EZH2 siRNA or control siRNA ( n = 3 per group). ( h ) Left, Representative immunofluorescence image of a-actinin (red)- and DAPI (blue)-stained NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE for 48 h. Scale bar, 100 μm. Right, Quantification of the average cell surface areas of NRCM transfected with miR-30d inhibitor and EZH2 siRNA before treated with or without PE. ( n = 4 per group, number of CM≥ 50 cells per sample). Data are presented as mean±SD. Statistical significance was determined by Student t test (b-c, e) and two-way ANOVA test with post hoc tukey (d, f-h). *, P < 0.05; **, P < 0.01 and ***, P < 0.001.

Article Snippet: EZH2 overexpression plasmid was purchased from vigenebio (CH882009, China).

Techniques: Modification, Quantitative RT-PCR, Expressing, Western Blot, Luciferase, Reporter Assay, Binding Assay, Over Expression, Plasmid Preparation, Negative Control, Control, Immunofluorescence, Staining, Transfection

Journal: eBioMedicine

Article Title: Targeting miR-30d reverses pathological cardiac hypertrophy

doi: 10.1016/j.ebiom.2022.104108

Figure Lengend Snippet:

Article Snippet: EZH2 overexpression plasmid was purchased from vigenebio (CH882009, China).

Techniques: Recombinant, Western Blot, Lysis, Staining, Software